Antipodes Partners LTD Janux Therapeutics, Inc. Transaction History
Antipodes Partners LTD
- $3 Billion
- Q2 2025
A detailed history of Antipodes Partners LTD transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Antipodes Partners LTD holds 1,048 shares of JANX stock, worth $25,152. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,048
Previous 632
65.82%
Holding current value
$25,152
Previous $17,000
41.18%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding JANX
# of Institutions
186Shares Held
55.9MCall Options Held
869KPut Options Held
652K-
Ra Capital Management, L.P. Boston, MA11.2MShares$269 Million5.65% of portfolio
-
Janus Henderson Group PLC London, X04.46MShares$107 Million0.05% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.92MShares$70.1 Million3.15% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.53MShares$60.6 Million0.1% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$56.3 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...